Fate Therapeutics (STU:F6T) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:F6T Fate Therapeutics Inc STU:F6T
39 GF Score
Price €2.21
GF Value €0.64
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Fate Therapeutics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Fate Therapeutics Quality Rank Related Terms

STU:F6T
39GF Score
Fate Therapeutics Inc STU:F6T
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Fate Therapeutics (STU:F6T) Overvalued in 2026?

Based on GuruFocus' analysis, Fate Therapeutics stock appears to be overvalued. The current stock price of €2.21 is trading 244.7% above its estimated GF Value™ of €0.64. GuruFocus considers Fate Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:F6T:

  • Quality Rank:
  • GF Value™: €0.64 vs. price of €2.21 (244.7% above fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the STU:F6T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fate Therapeutics Business Description

Other Exchanges FATE:USA
Address 12278 Scripps Summit Drive, San Diego, CA, USA, 92131
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
39GF Score

Get the complete analysis for STU:F6T

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.21
Price
€0.64
GF Value